Abstract
Quantitative structure-activity relationships (QSAR) of 65 different molecular series histone deacetylase inhibitors (HDACIs) with only one common pyrrole ring were studied by using comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA) and hologram quantitative structure-activity relationship (HQSAR). The leave-one-out cross-validation q2 values of CoMFA, CoMSIA and HQSAR models were 0.623, 0.662 and 0.716, and non-cross-validated r2 values were 0.952, 0.909 and 0.891, respectively. The contour maps and atom contribution map provided helpful visualization information for structural modification of the HDACIs for better activity. A further docking study was carried out by using Surflex-dock method. Sixty-five compounds were docked into histone deacetylase (PDB ID 1T64). A reasonable docking model between inhibitors and the protein was obtained. The interaction between ligands and the receptor can reveal the binding mode of the HDAC inhibitors and HDAC enzyme. According to QSAR and docking results, eight new molecules were proposed, and their activities were predicted by using the established QSAR model and docking method. The results indicated that the proposed potential molecules have a potent activity.
Keywords: CoMFA, CoMSIA, HQSAR, HDACIs, Surflex-dock
Letters in Drug Design & Discovery
Title:QSAR and Docking Studies on Different Series of Histone Deacetylase Inhibitors (HDACIs)
Volume: 9 Issue: 4
Author(s): Yuhong Xiang, Liang Zhang, Zhuoyong Zhang
Affiliation:
Keywords: CoMFA, CoMSIA, HQSAR, HDACIs, Surflex-dock
Abstract: Quantitative structure-activity relationships (QSAR) of 65 different molecular series histone deacetylase inhibitors (HDACIs) with only one common pyrrole ring were studied by using comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA) and hologram quantitative structure-activity relationship (HQSAR). The leave-one-out cross-validation q2 values of CoMFA, CoMSIA and HQSAR models were 0.623, 0.662 and 0.716, and non-cross-validated r2 values were 0.952, 0.909 and 0.891, respectively. The contour maps and atom contribution map provided helpful visualization information for structural modification of the HDACIs for better activity. A further docking study was carried out by using Surflex-dock method. Sixty-five compounds were docked into histone deacetylase (PDB ID 1T64). A reasonable docking model between inhibitors and the protein was obtained. The interaction between ligands and the receptor can reveal the binding mode of the HDAC inhibitors and HDAC enzyme. According to QSAR and docking results, eight new molecules were proposed, and their activities were predicted by using the established QSAR model and docking method. The results indicated that the proposed potential molecules have a potent activity.
Export Options
About this article
Cite this article as:
Yuhong Xiang, Liang Zhang, Zhuoyong Zhang , QSAR and Docking Studies on Different Series of Histone Deacetylase Inhibitors (HDACIs), Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799860033
DOI https://dx.doi.org/10.2174/157018012799860033 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Recent Advances in Pharmacokinetics of Polymeric Excipients Used in Nanosized Anti-Cancer Drugs
Current Drug Metabolism Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study
Current Drug Targets Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.
Reviews on Recent Clinical Trials The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma
Current Drug Targets Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Drugs, Trials and Pathogenesis: Will Connecting these Help us Understand SLE?
Current Rheumatology Reviews Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Preparation and Quality Control of <sup>111</sup>In-Plerixafor for Chemokine Receptor CXCR4
Recent Patents and Topics on Imaging (Discontinued) MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview
Anti-Cancer Agents in Medicinal Chemistry Cathelicidins - Natures Attempt at Combinatorial Chemistry
Combinatorial Chemistry & High Throughput Screening Abscopal Effect of Radiation Therapy and Signal Transduction
Current Signal Transduction Therapy Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Regulation of Arylamine N-Acetyltransferases
Current Drug Metabolism